Khyber Teaching Hospital
Peshawar, Khyber Pukhtunkhwa, 25000, Pakistan
Location status: Recruiting
NCT Number: NCT06939959
This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to artificial tears in improving the ocular surface interface in patients with dry eye disease over 1 year period.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
Peshawar, Khyber Pukhtunkhwa, 25000, Pakistan
Location status: Recruiting
Patients fulfilling the selection criteria will be enrolled from eye OPD of KTH. A written informed consent will be taken after explaining the purpose of study. Data will be collected on a pre-designed structured proforma. Demographic data including age, gender, educational status, socioeconomic status will be noted. Each participant will undergo a complete history assessment and the OSDI score will be calculated after taking extensive history. Ophthalmologic examination, including visual acuity, refraction, slit-lamp examination, corneal staining, schirmer test and TBUT will be performed in each patient. Both eyes will be selected for each secondary outcome measure (TBUT & SCHIRMER TEST). However, only one OSDI score could only be obtained per patient for assessing primary outcome. All the previous medications used for dry eye will be stopped Participants' eyes will be randomized by blocked randomization in a 1:1 ratio to be treated with topical artificial tears (group I) and topical insulin 1U/ml (group II). The patients will be masked for the treatment, but not the principle investigator. Another investigator will prepare the topical insulin according to a written protocol. Participants will be given a white, unlabeled eye dropper containing the same volume of artificial tears or topical insulin for groups I and II respectively. Group I will receive artificial tears (control group) four times daily. Group II will receive topical insulin of 1u/ml four times daily. Follow-up assessments will be conducted at 4, 8 and 12 weeks for each participant to measure changes in TBUT, schirmer test, and OSDI score.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
commercially available artificial tears will be used consisting of same ingredients.
Other names: ARTIFICIAL TEARS
injection humulin will be used to make topical insulin drops
Other names: HUMULIN INSULIN
Time frame: 12 weeks or 3 months
The treatment will be deemed effective if OSDI score of less than 20 is achieved at 12 weeks of the initiation of treatment
Time frame: 12 weeks or 3 months
The treatment will be deemed effective if Schirmer's test values are above 10mm after 5 minutes, TBUT of more than 10 seconds s achieved at 12 weeks of the initiation of treatment.
Contact information is provided by the study sponsor or research team.
Khyber Teaching Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05692739
Dry Eye, Dry Eye Syndromes
Madrid, Spain
View Trial DetailsNCT06931041
Arthritis, Arthritis, Rheumatoid
Mexico City, Mexico
View Trial DetailsNCT07705893
Dry Eye, Dry Eye Syndromes
Houston, Texas, United States
View Trial DetailsNCT07413172
Dry Eye, Dry Eye Syndromes
Miami, Florida, United States
View Trial Details